Last reviewed · How we verify

Medtronic Cardiac Rhythm and Heart Failure — Portfolio Competitive Intelligence Brief

Medtronic Cardiac Rhythm and Heart Failure pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Flecainide or Sotalol or Propafenone Flecainide or Sotalol or Propafenone phase 3 Antiarrhythmic agents (Class I and Class III) Cardiac sodium channels (Flecainide, Propafenone); cardiac potassium channels and beta-adrenergic receptors (Sotalol) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Medtronic Cardiac Rhythm and Heart Failure:

Cite this brief

Drug Landscape (2026). Medtronic Cardiac Rhythm and Heart Failure — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medtronic-cardiac-rhythm-and-heart-failure. Accessed 2026-05-17.

Related